Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials.

ABSTRACT:

Background

Racial differences have been reported in toxicity outcomes for anticancer drug treatments. However, these observations were often from studies with small sample sizes, and many only reported the maximum grade of toxicity and no longitudinal information. This current analysis aims to investigate racial differences in longitudinal toxicities using a large-scale clinical trials database.

Methods

Early-phase clinical trials sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute, USA, that evaluated cytotoxic drugs and molecularly targeted agents between March 2000 and December 2012 were studied. Race was categorized as White, Black or African-American, and Asian. Each toxicity's grade prevalence, mean grade at each cycle, and time to devel

SUBMITTER: Mizusawa J 

PROVIDER: S-EPMC10524029 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature